期刊文献+

MiR-145对人结肠癌细胞株HCT-116奥沙利铂耐药机制探讨 被引量:8

Role of miR-145 in the acquired resistance to Oxaliplatin of human colon cancer cell line HCT-116
原文传递
导出
摘要 目的探讨microRNA 145(miR-145)对人结肠癌细胞株HCT-116奥沙利铂(L-OHP)耐药作用及其机制。方法采用逐步增加药物浓度的方法,建立人结肠癌耐奥沙利铂细胞株HCT-116/L-OHP。脂质体转染法将miR-145转入建立好的耐药细胞株中,并设立阴性miRNA对照组、miR-145siRNA处理组(miR-145组)、空脂质体组和空白对照组(control组)。MTT法测定转染48h后细胞增殖能力和对L-OHP的敏感性;实时定量PCR检测转染后HCT-116/L-OHP细胞中多药耐药基因MDR1和抑癌基因PTEN的表达;蛋白质印迹法检测P-糖蛋白(P-gp)和PTEN蛋白表达。结果成功建立耐药倍数为母本细胞7倍的HCT-116/L-OHP细胞株。检测HCT-116母本与HCT-116/L-OHP细胞MDR1、PTEN基因表达结果显示,HCT-116/L-OHP细胞MDR1基因水平为0.86±0.05,较母本细胞的0.39±0.03显著升高;HCT-116/L-OHP细胞PTEN基因水平为0.41±0.04,较母本细胞的0.89±0.02显著下调。应用miR-145转染母本及耐药细胞发现,miR-145可明显抑制HCT-116母本及HCT-116/L-OHP细胞的增殖,生长抑制率分别为57%和38%,进而提高细胞对L-OHP的药物敏感性。进一步研究发现,miR-145过表达处理后,抑癌基因PTEN表达水平为0.78±0.03,较control组的0.42±0.01显著上调;而MDR1基因表达水平为0.47±0.01,较control组的0.87±0.02显著下调。经miR-145siRNA预处理后,HCT-116/L-OHP细胞抑癌基因PTEN表达水平为0.35±0.02,较miR-145组显著下降;而MDR1基因表达水平为0.94±0.04,较miR-145组显著上调;PTEN蛋白及MDR1目的蛋白P-gp的变化呈现相同趋势,P值均<0.05。结论 miR-145可降低人结肠癌HCT-116细胞株奥沙利铂耐药性,其作用机制可能是通过影响MDR1和PTEN基因及蛋白表达水平来实现的。 OBJECTIVE To investigate the possible mechanism of miR-145 in the drug resistance to Oxaliplatin (L-OHP) of human colon cancer cell line HCT-116. METHODS L-OHP-resistant human colon cancer cell line (HCT-116/L OHP) was established in vitro by exposuring to increased concentrations of L-OHP in cell culture medium, and miR 145 transfection was made by liposome. MTT(3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro- mide) assay was used to assess the proliferation and sensitivity to L-OHP of HCT ll6/L-OHP cells. The expression lev- els of MDR1 and PTEN gene and protein were detected by PCR and western blotting after pretreatment with the chemi- cally synthesized miR-145 siRNA. RESULTS Successful established a HCT-116 / L-OHP cell line as 7 times drug-resist- ant to the HCT 116 cell line. The MDR1, PTEN gene expression in both cell line showed that MDR1 gene level of HCT-116/L-OHP cells (0.86±0.05) was significantly higher than that of parental cells (0. 39± 0.03), while PTEN gene level (0.41+0.04) was significantly lower than that of the parent cell (0. 89 ± 0.02); miR-145 transfection de creased the proliferation and increased sensitivity to L OHP of both HCT-116 and HCT-116/L OHP cells, the growth in hibition rate was 57 %0 and 38 G respectively. Further mechanism analysis showed that after miR 145 transfection,the mR NA expression of PTEN (0.78±0.03) was significantly increased compared with the control group (0.42±0.01), while the expression of MDR1 (0.47±0.01) was decreased compared with the control group (0.87±0.02). Further analysis confirmed that pretreatment with miR-145 siRNA showed a decrease of PTEN (0. 35 ± 0. 02) and increase of MDR1 (0.94±0.04) ,the protein expression changes of both PTEN and P-gp showed a same trend (both P〈0.05). CONCLU- SIONS miR-145 decreased the proliferation and increased sensitivity to L-OHP of HCT-116/L OHP cells probably by regulating the gene and protein expression of MDR1 and PTEN. Consequently, our findings may provide a potential target for treatment of colon cancer platinum drug resistance.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2015年第19期1523-1527,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 河南省科技厅科技创新人才计划(201301014)
关键词 结肠肿瘤 MICRORNA 145 HCT-116细胞 耐药 奥沙利铂 印迹法 蛋白质 colonic neoplasms microRNA-145 HCT-116 cells drug resistance Oxaliplatin blotting, western
  • 相关文献

参考文献23

  • 1KantolaT, Klintrup K, Vyrynen J, et al. Stage-dependent al- terations of the serum cytokine pattern in colorectal carcinoma [J]. Brit J Cancer, 2012, 107(10): 1729-1736.
  • 2鲁小敏,刘晓岗.伊立替康联合雷替曲塞治疗晚期结直肠癌30例临床观察[J].交通医学,2015,29(1):56-58. 被引量:7
  • 3赵波,钟华戈,吴卫,唐卫中.结直肠癌危险因素的流行病学研究进展[J].结直肠肛门外科,2013,19(3):199-202. 被引量:32
  • 4汪建平.重视结直肠癌流行病学研究[J].中国实用外科杂志,2013,33(8):622-624. 被引量:81
  • 5陈建芳,梁后杰,邹岚,蒋金妍,陈克力,王东,廖玲.ERCC5基因+25A>G多态性与晚期结直肠癌铂类药物疗效的相关性[J].临床肿瘤学杂志,2011,16(1):9-13. 被引量:3
  • 6Ametller E, Garcia-Recio S, Pastor-Arroyo EM, et al. Differen tial regulation of MMP7 in colon cancer cells resistant and sensi- tive to oxaliplatin-induced cell death [J]. Cancer Biol Ther, 2011, 11(1).. 4-13.
  • 7Kala R, Peek GW, Hardy TM, et al. MicroRNAs: an emerging science in cancer epigenetics [J]. J Clin Bio, 2013, 3(1): 6.
  • 8Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks [J]. J Mol Biol, 2013, 425(19): 3582- 3600.
  • 9Fu X, Tian J, Zhang L, et al. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin ehemosensitivity in ovarian canc- er cells [J]. FEBS Lett, 2012, 586(9) : 1279-1286.
  • 10Zhao L, Liu W, Xiao J, et al. The role of exosomes and "exoso- mal shuttle microRNA" in tumorigenesis and drug resistance [J].Caneer Lett, 2015, 356(2): 339-346.

二级参考文献196

共引文献231

同被引文献45

引证文献8

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部